Transdermal fentanyl matrix, gabapentin ( DrugBank: Fentanyl, Gabapentin )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 70 | Spinal stenosis | 1 |
70. Spinal stenosis
Clinical trials : 95 / Drugs : 169 - (DrugBank : 61) / Drug target genes : 68 - Drug target pathways : 90
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01127100 (ClinicalTrials.gov) | May 2010 | 19/5/2010 | Gabapentin Versus Transdermal Fentanyl Matrix for Chronic Neuropathic Pain | Gabapentin Versus Transdermal Fentanyl Matrix (TDF) for Chronic Neuropathic Pain (of Radicular Origin): A Multicenter Randomized, Parallel Group, Rater Blinded, Non-inferiority Trial | Neuropathic Pain;Spinal Stenosis | Drug: transdermal fentanyl matrix, gabapentin | Seoul National University Hospital | Seoul National University Bundang Hospital;Asan Medical Center;Inje University;Chonnam National University Hospital;Chung-Ang University Hosptial, Chung-Ang University College of Medicine;Dankook University | Completed | 20 Years | 80 Years | Both | 108 | Phase 4 | Korea, Republic of |